We are investigating Global Cord Blood Corporation (“Global Cord Blood” or the “Company”), and its officers and directors, for potential misconduct in connection with its planned acquisition of Cellenkos, Inc, that the Company announced on April 29, 2022.

On May 9, 2022, Global Cord Blood announced that one of its major investors filed a notice of a winding up petition in the Grand Court of the Cayman Islands, seeking an order that the Company be required to refrain from its planned acquisition of Cellenkos and that certain shareholder protections be enacted. The proceedings in the Grand Court of the Cayman Islands then revealed potential misconduct by Global Cord Blood’s officers and directors in connection with its planned acquisition of Cellenkos, including the potential misappropriation of hundreds of millions of dollars from the Company.  After Global Cord Blood announced the Cellenkos transaction on April 29, 2022, its stock price fell $0.98 per share, or 28%, to close at $2.45 per share on May 2, 2022, the next trading day.  

If you own shares of Global Cord Blood, we may be able to recover losses incurred by the company as part of the above. To learn more, please fill out the form below for a no-cost, risk-free, and completely confidential consultation. 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Learn More!